TRBC1 specific Immunotherapy showing promise for T cell Lymphoma treatment
Autolus Therapeutics tested the toxicity and efficacy of AUTO4, a TRBC1 specific CAR cell therapeutic on 10 relapsed/refractory T cell lymphoma patients. This treatment appears to be safe with only minimal toxicity. The CAR T cells were shown to be residing in the majority of patient lymph nodes.Ancell anti-TRBC1/Biotin (clone Jovi-1) was used to sort […]
TRBC1 specific Immunotherapy showing promise for T cell Lymphoma treatment Read More »